Ocera Therapeutics
Posted on: November 4, 2017
By: Kim Berlowitz
With: Comments Off on Ocera Therapeutics
Clinical-stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous (IV) and oral formulations